Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 vs 13q12 3 Microdeletion Syndrome C4750951
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete CN042980 and 13q12 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
A rare enzyme deficiency affecting hormone production, leading to low sex hormones and elevated blood pressure. Lifelong hormone replacement therapy is typically needed. Ongoing medical monitoring helps manage associated health concerns.
13q12 3 Microdeletion Syndrome C4750951
A rare genetic condition where a small piece of chromosome 13 is missing. It can cause various developmental and medical concerns. Care is supportive and tailored to the individual's needs.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
0-null
13q12 3 Microdeletion Syndrome C4750951
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
severe
13q12 3 Microdeletion Syndrome C4750951
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Chronic
13q12 3 Microdeletion Syndrome C4750951
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
No
13q12 3 Microdeletion Syndrome C4750951
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
13q12 3 Microdeletion Syndrome C4750951
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
13q12 3 Microdeletion Syndrome C4750951
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-complete-CN042980 and 13q12-3-microdeletion-syndrome-C4750951 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 13q12 3 Microdeletion Syndrome C4750951 | Discriminating power |
|---|---|---|---|
| Blood pressure and puberty | May include hypertension and reduced sex-hormone effects, including delayed or absent puberty. | Blood pressure and puberty are not defining features in the supplied description. | High |
| Development | Primary concern is hormonal rather than a described developmental syndrome. | May involve variable developmental and other medical concerns. | Moderate |
| Cause | Enzyme deficiency disrupting steroid hormone production. | Missing small segment at chromosome 13q12.3. | High |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 when
Hypertension with suspected sex-hormone deficiency
This pattern fits the described endocrine enzyme disorder better than a chromosomal syndrome.
Moderate
Abnormal steroid pathway evaluation
Clinician-directed hormone testing can support an enzyme-deficiency diagnosis.
Moderate
Planning lifelong hormone care
The source states hormone replacement and monitoring are typically needed.
High
Choose 13q12 3 Microdeletion Syndrome C4750951 when
Developmental concerns with suspected chromosomal change
The description centers on variable developmental and medical effects of a microdeletion.
Moderate
Confirmed 13q12.3 deletion
Genetic confirmation distinguishes it from an endocrine enzyme diagnosis.
High
Need for individualized supportive care
Care is described as supportive and tailored rather than hormone-specific.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 13q12 3 Microdeletion Syndrome C4750951 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Pattern may suggest impaired 17-hydroxylase/17,20-lyase activity; cutoffs are not supplied. | No characteristic steroid abnormality is established here. | Interpret only with specialist endocrine review. |
| Blood pressure and electrolytes | Hypertension may occur; exact electrolyte findings are not specified. | No consistent blood-pressure or electrolyte pattern is supplied. | An abnormal result is not itself a diagnosis. |
| Chromosomal microarray | Not the defining test for this enzyme deficiency. | May identify a 13q12.3 microdeletion when clinically indicated. | Genetic results require clinical correlation and counseling. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
- Outcome
- Often requires lifelong hormone replacement and monitoring; individual outcome is variable.
- Factors
- Blood pressure control, hormone management, and associated health concerns.
13q12 3 Microdeletion Syndrome C4750951
- Outcome
- Course varies with developmental and medical findings; supportive care is central.
- Factors
- Specific deleted genes, associated anomalies, and available therapies are not detailed here.
Time frame: Both are chronic, often from early life, but exact onset is not established.
Diagnosis confirmation, complications, and access to specialist care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiovascular or electrolyte effects | Elevated blood pressure is a stated concern and needs monitoring. No specific cardiovascular complication is established by the source. Do not infer exact risks or laboratory thresholds. |
| Reproductive development | Low sex hormones may affect puberty and fertility; individual effects vary. Reproductive outcome is not established in the supplied data. Specialist assessment is required. |
| Developmental disability | Not described as a core feature. Developmental concerns may occur but their range is not fully defined. Support should match assessed needs. |
Patient education highlights
- HighDifferent causes
One is a hormone-production enzyme disorder; the other is a chromosomal microdeletion. Tests and care differ.
- HighMonitoring
Both are chronic. Endocrine follow-up is typical for the enzyme disorder, while microdeletion care is individualized.
- MediumAvoid unsupported numbers
Prevalence, exact cutoffs, mortality, and treatment doses are not established here and should come from clinicians.